1. Home
  2. CFND vs MDXH Comparison

CFND vs MDXH Comparison

Compare CFND & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C1 Fund Inc.

CFND

C1 Fund Inc.

HOLD

Current Price

$3.01

Market Cap

22.1M

Sector

N/A

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.42

Market Cap

21.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
MDXH
Founded
N/A
2003
Country
Belgium
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
22.1M
21.1M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CFND
MDXH
Price
$3.01
$0.42
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
23.0K
325.5K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.85
$0.40
52 Week High
$9.67
$5.33

Technical Indicators

Market Signals
Indicator
CFND
MDXH
Relative Strength Index (RSI) 36.47 34.72
Support Level $2.85 N/A
Resistance Level $3.53 $3.79
Average True Range (ATR) 0.10 0.02
MACD -0.03 0.02
Stochastic Oscillator 13.13 28.30

Price Performance

Historical Comparison
CFND
MDXH

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company. The Adviser provides day-to-day investment management services to the Company, which is classified as non-diversified under the Investment Company Act. The Company's investment objective is to maximize its portfolio's total return by principally investing in privately held equity and equity-linked securities of digital asset services and technology companies. Its investments in equity securities include common and preferred shares, securities convertible into common shares, warrants and rights to subscribe to or purchase common shares, and common shares carrying a warrant or right.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: